Skip to main content Skip to main navigation menu Skip to site footer

Patent foramen ovale and cryptogenic stroke: still needs a complete study

  • Herlina Dimiati ,
  • Rico Rasaki ,


Patent foramen ovale (PFO) is a residual of normal fetal anatomy. More than half of babies will develop PFO at six months of age. PFO may cause shunts from right to left, and the possibility for shunting from venous thromboembolism into the arterial circulation. Since then, many idiopathic stroke studies have been conducted, in which PFOs are often found. PFO does not require follow-up treatment in infants and children, and venous thromboembolism should also be evaluated for idiopathic stroke in young patients to assess the trend of thromboembolism associated with PFO, which affects morbidity and mortality. The decision to treat depends on the presence, size and presence of complications.


  1. Homma S, Di Tullio MR. Patent foramen ovale and stroke. J Cardiol. 2010/06/29. 2010;56(2):134–41. Available from:
  2. Collado FMS, Poulin M-F, Murphy JJ, Jneid H, Kavinsky CJ. Patent Foramen Ovale Closure for Stroke Prevention and Other Disorders. J Am Heart Assoc. 2018;7(12):e007146. Available from:
  3. P. Pinto Pereira S, Nunes A, Santos C, E. Kasner S, P. L. Nunes J. The Role of Patent Foramen Ovale Closure in the Secondary Prevention of Cryptogenic Stroke: a Meta-Analysis Report. Int J Cardiovasc Sci. 2019; Available from:
  4. Yuan K, Kasner SE. Patent foramen ovale and cryptogenic stroke: diagnosis and updates in secondary stroke prevention. Stroke Vasc Neurol. 2018;3(2):84–91. Available from:
  5. Kutty S, Sengupta PP, Khandheria BK. Patent Foramen Ovale. J Am Coll Cardiol. 2012;59(19):1665–71. Available from:
  6. Agnetti A, Carano N, Sani E, Tchana B, Allegri V, Bernasconi S, et al. Cryptogenic Stroke in Children: Possible Role of Patent Foramen Ovale. Neuropediatrics. 2006;37(1):53–6. Available from:
  7. Pickett CA, Villines TC, Ferguson MA, Hulten EA. Percutaneous closure versus medical therapy alone for cryptogenic stroke patients with a patent foramen ovale: meta-analysis of randomized controlled trials. Texas Hear Inst J. 2014;41(4):357–67. Available from:
  8. Ntaios G, Papavasileiou V, Sagris D, Makaritsis K, Vemmos K, Steiner T, et al. Closure of Patent Foramen Ovale Versus Medical Therapy in Patients With Cryptogenic Stroke or Transient Ischemic Attack. Stroke. 2018;49(2):412–8. Available from:
  9. Das BB. Patent Foramen Ovale in Fetal Life, Infancy and Childhood. Med Sci (Basel, Switzerland). 2020;8(3):25. Available from:
  10. Parrini I, Cecchi E, Forno D, Lyon AR, Asteggiano R. Device closure for patent foramen ovale in patients with cryptogenic stroke: which patients should get it? Eur Heart J Suppl. 2020;22(Suppl M):M43–50. Available from:
  11. Hubail Z, Lemler M, Ramaciotti C, Moore J, Ikemba C. Diagnosing a Patent Foramen Ovale in Children. Stroke. 2011;42(1):98–101. Available from:
  12. Rana BS, Thomas MR, Calvert PA, Monaghan MJ, Hildick-Smith D. Echocardiographic Evaluation of Patent Foramen Ovale Prior to Device Closure. JACC Cardiovasc Imaging. 2010;3(7):749–60. Available from:
  13. Yaghi S, Bernstein RA, Passman R, Okin PM, Furie KL. Cryptogenic Stroke. Circ Res. 2017;120(3):527–40. Available from:
  14. Pristipino C, Anzola GP, Ballerini L, Bartorelli A, Cecconi M, Chessa M, et al. Management of patients with patent foramen ovale and cryptogenic stroke: A collaborative, multidisciplinary, position paper. Catheter Cardiovasc Interv. 2013;82(1):E38–51. Available from:
  15. Abdelghani M, El-Shedoudy SAO, Nassif M, Bouma BJ, de Winter RJ. Management of Patients with Patent Foramen Ovale and Cryptogenic Stroke: An Update. Cardiology. 2019;143(1–2):62–72. Available from:
  16. Valencia-Sanchez C, Fortuin FD, Sweeney JP, Ingall TJ, Marks LA, Wingerchuk DM, et al. Is Patent Foramen Ovale Closure More Effective Than Medical Therapy in Preventing Stroke Recurrence in Patients With Cryptogenic Stroke? Neurologist. 2018;23(5):175–80. Available from:
  17. Kottoor SJ, Arora RR. Cryptogenic Stroke: To Close a Patent Foramen Ovale or Not to Close? J Cent Nerv Syst Dis. 2018;10:1179573518819476–1179573518819476. Available from:
  18. Saver JL. Cryptogenic Stroke. N Engl J Med. 2016;374(21):2065–74. Available from:
  19. Bang OY, Lee MJ, Ryoo S, Kim SJ, Kim JW. Patent Foramen Ovale and Stroke-Current Status. J stroke. 2015/09/30. 2015;17(3):229–37. Available from:
  20. Kitsios GD, Dahabreh IJ, Abu Dabrh AM, Thaler DE, Kent DM. Patent foramen ovale closure and medical treatments for secondary stroke prevention: a systematic review of observational and randomized evidence. Stroke. 2011/12/15. 2012;43(2):422–31. Available from:
  21. Chun K-J. Patent Foramen Ovale and Cryptogenic Stroke. Korean Circ J. 2008;38(12):631. Available from:
  22. Niu X, Ou-Yang G, Yan P, Huang S, Zhang Z, Zhang Z. Closure of patent foramen ovale for cryptogenic stroke patients: an updated systematic review and meta-analysis of randomized trials. J Neurol. 2018;265(6):1259–68. Available from:
  23. Sagris D, Georgiopoulos G, Perlepe K, Pateras K, Korompoki E, Makaritsis K, et al. Antithrombotic Treatment in Cryptogenic Stroke Patients With Patent Foramen Ovale. Stroke. 2019;50(11):3135–40. Available from:
  24. Mojadidi MK, Zaman MO, Elgendy IY, Mahmoud AN, Patel NK, Agarwal N, et al. Cryptogenic Stroke and Patent Foramen Ovale. J Am Coll Cardiol. 2018;71(9):1035–43. Available from:
  25. Oto A, Aytemir K, Özkutlu S, Kaya EB, Yorgun H, Canpolat U, et al. Transthoracic Echocardiography Guidance during Percutaneous Closure of Patent Foramen Ovale. Echocardiography. 2011;28(10):1074–80. Available from:
  26. Furlan AJ, Reisman M, Massaro J, Mauri L, Adams H, Albers GW, et al. Closure or Medical Therapy for Cryptogenic Stroke with Patent Foramen Ovale. N Engl J Med. 2012;366(11):991–9. Available from:
  27. Meier B, Kalesan B, Mattle HP, Khattab AA, Hildick-Smith D, Dudek D, et al. Percutaneous Closure of Patent Foramen Ovale in Cryptogenic Embolism. N Engl J Med. 2013;368(12):1083–91. Available from:
  28. Carroll JD, Saver JL, Thaler DE, Smalling RW, Berry S, MacDonald LA, et al. Closure of Patent Foramen Ovale versus Medical Therapy after Cryptogenic Stroke. N Engl J Med. 2013;368(12):1092–100. Available from:
  29. Saver JL, Carroll JD, Thaler DE, Smalling RW, MacDonald LA, Marks DS, et al. Long-Term Outcomes of Patent Foramen Ovale Closure or Medical Therapy after Stroke. N Engl J Med. 2017;377(11):1022–32. Available from:
  30. Mas J-L, Derumeaux G, Guillon B, Massardier E, Hosseini H, Mechtouff L, et al. Patent Foramen Ovale Closure or Anticoagulation vs. Antiplatelets after Stroke. N Engl J Med. 2017;377(11):1011–21. Available from:
  31. Søndergaard L, Kasner SE, Rhodes JF, Andersen G, Iversen HK, Nielsen-Kudsk JE, et al. Patent Foramen Ovale Closure or Antiplatelet Therapy for Cryptogenic Stroke. N Engl J Med. 2017;377(11):1033–42. Available from:
  32. Varotto L, Bregolin G, Paccanaro M, De Boni A, Bonanno C, Perini F. The Closure of Patent Foramen Ovale in Preventing Subsequent Neurological Events: A Bayesian Network Meta-Analysis to Identify the Best Device. Cerebrovasc Dis. 2020;49(2):124–34. Available from:

How to Cite

Dimiati, H., & Rasaki, R. (2021). Patent foramen ovale and cryptogenic stroke: still needs a complete study. Bali Medical Journal, 10(2), 663–667.




Search Panel